Sekisui Diagnostics, Spectrolyse PAI-1 In-Vitro Diagnostic Use for the quantitative determination of Plasminogen Activator Inhibitor Type 1 in human plasma. Catalog # 101201. Spectrolyse PAI-1 is intended for the quantitative determination of Plasminogen Activator Inhibitor Type-1 (PAI-1) activity in human plasma. The test is for in vitro diagnostic use.
Published December 12, 2012 · Recall initiated: October 24, 2012
Summary
FDA records medical device Class II recall Z-0463-2013, published December 12, 2012 and initiated October 24, 2012. Recalling firm: Sekisui Diagnostics Llc; Status: Terminated; Reported quantity: 63 kits; Lot: Lot # 120827, exp 11/27/2012. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Spectrolyse PAI-1 activity assay, producing lower than expected absorbance values 0 IU/ml standard reducing the slope of the standard curve requiring more frequent sample dilutions.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Sekisui Diagnostics Llc
- Distributor
- Nationwide Distribution-including the states of FL, IN, NC, OH, UT, and WA.
- Lot
- Lot # 120827, exp 11/27/2012
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDA24 Fr 8mm Soft Flow Ang W/L The Sarns Aortic Cannula is indicated for use in perfusion of the ascending aortaDecember 12, 2012
- FDACustom Procedural Trays: Merit's Custom Total Hip Pack, K12T-05537, Merit's Total Knee Pack, K12T05538 ADecember 12, 2012
- FDA24 Fr 8mm Soft Flow Ang Wire W/L The Sarns Aortic Cannula is indicated for use in perfusion of the ascendingDecember 12, 2012
- FDASiemens syngo.plaza Radiological Image Processing System Usage: Radiological Image Processing SystemDecember 12, 2012
- FDASekisui Spectrolyse PAI-1, In-Vitro Diagnostic for Quantitative determination of Plasminogen ActivatorSeptember 26, 2012
- FDAMULTIGENT Acetaminophen for use with Architect/Aeroset Cat. No. 2K99-20. Assay is intended for theJuly 4, 2012
Questions about this recall
Was Sekisui Diagnostics, Spectrolyse PAI-1 In-Vitro Diagnostic Use for the quantitative determination of Plasminogen Activator Inhibitor Type 1 in human plasma. Catalog # 101201. Spectrolyse PAI-1 is intended for the quantitative determination of Plasminogen Activator Inhibitor Type-1 (PAI-1) activity in human plasma. The test is for in vitro diagnostic use. recalled?
Yes. FDA published recall Z-0463-2013 on December 12, 2012. Reported hazard: Spectrolyse PAI-1 activity assay, producing lower than expected absorbance values 0 IU/ml standard reducing the slope of the standard curve requiring more frequent sample dilutions.
What should I do if I have this product?
Voluntary: Firm initiated · Letter